Dalzanemdor

Sage Therapeutics halts development of dalzanemdor after disappointing Phase II results in Huntington's disease, marking the third failed indication for the NMDA modulator.

Sage Therapeutics has stopped the development of dalzanemdor (SAGE-718) for Huntington's disease (HD) after disappointing results from the Phase 2 DIMENSION study.

Sage Therapeutics' dalzanemdor (SAGE-718) failed to meet key goals in a Phase 2 study for cognitive impairment in Huntington's disease, leading to the program's discontinuation.

Sage Therapeutics has stopped the development of dalzanemdor for Huntington's disease after it failed to meet the primary endpoint in the Phase II DIMENSION study.

Sage Therapeutics' Phase 2 DIMENSION study of dalzanemdor (SAGE-718) in Huntington's Disease-associated cognitive impairment did not meet its primary endpoint.